anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a grip, for covering a writing utensil or a cosmetic goods, which can be easily inserted into and removed from a writing utensil or a cosmetic goods and ensures its firm and tight fastening to the utensil or the goods during using the grip and the constitution of the writing utensil or the cosmetic goods using the grip.  <P>SOLUTION: This grip 2 covers a stick-like writing utensil or a cosmetic goods 1 with a nearly regular polygonal cross section from outside and has an inside face of a nearly regular polygonal shape which comes into contact with the outside face of a writing utensil or a cosmetic goods 1 in the entire longitudinal region or some of a plurality of the regions. In addition, the maximum diameter of the nearly regular polygon specifying the inside face is set larger than the maximum diameter of the nearly regular polygonal cross section of the writing utensil or the cosmetic goods 1 and the minimum diameter of the nearly regular polygon specifying the inside face is set smaller than the maximum diameter of the polygonal cross section of the writing utensil or the cosmetic goods 1. Based on these settings, the grip 2 can be attached to and detached from the writing utensil or the cosmetic goods 1 which allows the fitting/removing operation and the firm and tight fastening condition of the grip 2. Also the writing utensil or the cosmetic goods 1 using the grip 2 are provided.  <P>COPYRIGHT: (C)2003,JPO
Chemotherapy-induced neuropathic pain (CIPN) is a common side effect of antitumor chemotherapeutic agents. It describes a pathological state of pain related to the cumulative dosage of the drug, significantly limiting the efficacy of antitumor treatment. Sofas strategies alleviating CIPN still lack. Calcitonin gene-related peptide (CGRP) is a neuropeptide involved in many pathologic pains. In this study, we explored the effects of CGRP blocking on CIPN and potential mechanisms. Total dose of 20.7 mg/kg cisplatin was used to establish a CIPN mouse model. Mechanical and thermal hypersensitivity was measured using von Frey hairs and tail flick test. Western blot and immunofluorescence were utilized to evaluate the levels of CGRP and activated astrocytes in mouse spinal cord, respectively. In addition, real-time quantitative PCR (RT-qPCR) was used to detect the level of inflammatory cytokines such as IL-6, IL-1β, and NLRP3 in vitro and in vivo. There are markedly increased CGRP expression and astrocyte activation in the spinal cord of mice following cisplatin treatment. Pretreatment with a monoclonal antibody targeting CGRP (ZR8 mAb) effectively reduced cisplatin-induced mechanical hypersensitivity and thermal nociceptive sensitization and attenuated neuroinflammation as marked by downregulated expression of IL-6, IL-1β, and NLRP3 in the mice spinal cord and spleen. Lastly, ZR8 mAb does not interfere with the antitumor effects of cisplatin in tumor-bearing mice. Our findings indicate that neutralizing CGRP with monoclonal antibody could effectively alleviate CIPN by attenuating neuroinflammation. CGRP is a promising therapeutic target for CIPN.
Here we present application of innovative lab-made analytical devices such as plasmonic silver nanostructured substrates and polypyrrole-MOF solid-phase microextraction fibers for metabolic profiling of bacteria. For the first time, comprehensive metabolic profiling of both volatile and non-volatile low-molecular weight compounds in eight bacterial strains was carried out with utilization of lab-made devices. Profiles of low molecular weight metabolites were analyzed for similarities and differences using principal component analysis, hierarchical cluster analysis and random forest algorithm. The results showed clear differentiation between Gram positive (G+) and Gram negative (G-) species which were identified as distinct clusters according to their volatile metabolites. In case of non-volatile metabolites, differentiation between G+ and G- species and clustering for all eight species were observed for the chloroform fraction of the Bligh & Dyer extract, while methanolic fraction failed to recover specific ions in the profile. Furthermore, the results showed correlation between volatile and non-volatile metabolites, which suggests that lab-made devices presented in the current study might be complementary and therefore, useful for species differentiation and gaining insights into bacterial metabolic pathways.
We have previously reported that TP53 (encoding p53 protein), one of the most frequently mutated genes in human cancers, dose dependently modulates the balance between the utilization of oxidative and glycolytic pathways for energy generation in human colon cancer cells and mouse liver mitochondria. Though morphologically similar to their wild-type littermates, mice deficient in p53 display a gene dose-dependent decrease in aerobic exercise capacity, implying that p53 has functions beyond its well characterized cell cycle activities. These current findings have broad implications in fields ranging from cancer and aging research to cardiovascular physiology.

In the Li-Fraumeni familial cancer syndrome (LFS), affected individuals harbor a germline mutation in TP53, hence they are heterozygous with reduced wild-type p53 activity. We hypothesize that the heterozygous individuals will display alterations in aerobic capacity and metabolism that previously has been unappreciated. This IRB proposal translates our experimental observation to human subjects in collaboration with extramural groups studying this rare familial syndrome. The results may not only help clarify why mutations of p53 gene are so common in cancers by potentially conferring metabolic advantages in tumorigenesis, but they may also give us an opportunity to understand a fundamental regulatory mechanism in cellular energy generation relevant to other processes.
Provided are fluorinated analogs of MDMA, including fluorinated empathogens. In some embodiments, such compounds are monoamine releasers or inhibit monoamine transporters. In some aspects, features of the compounds provide stability, such as metabolic stability, and efficacy. Also provided are methods for the preparation of fluorinated empathogens and pharmaceutical compositions comprising the same. Methods of using the fluorinated empathogens, alone or in combination with other therapeutic agents, are provided. In some embodiments, fluorinated empathogens are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders.
FIELD: medicine, oncology. SUBSTANCE: the present innovation deals with metastatic pleuritis in case of malignant tumors of different localization. The method includes intrapleural injection of antitumor preparations. Patient's autoblood is sampled at the quantity of 100-150 ml into sterile vial with hemoconservant to be centrifuged at ν rot  being 1500 rot./min for 30 min, 20 ml supernatant plasma is taken to solve there a single dose of cytostatic and incubate at 37C for 30 min. The rest cellular part and plasma should be reinfused. Under local anesthesia one should puncture pleural cavity, maximum evacuate pleural exudates and introduce prepared autoplasma with cytostatic intrapleurally. This procedure should be repeated if necessary. The present innovation provides low toxicity of chemopreparations and low cost of therapy due to applying modified properties of autoplasma. EFFECT: higher efficiency of therapy. 2 dwg
Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics \[a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner\] are covered as those in the asthma in-school classes.
BACKGROUND AND AIMS: Diabetic gastroparesis (DGp) is a common and preventable complication of uncontrolled diabetes mellitus (D.M.) and significantly affects the Quality of Life of patients. Diagnosis and management present as a clinical challenge due to the disease's complexity and limited effective therapeutic options. This review aims to comprehensively outline the pathogenesis, diagnosis, and management of diabetic gastroparesis, evaluating evolving approaches to guide clinicians and provide future recommendations.
METHODS: A literature review was conducted on scholarly databases of PubMed, Google Scholar, Scopus and Web of Science encompassing published articles, gray literature and relevant clinical guidelines. Data were synthesized and analyzed to provide a comprehensive overview of diabetic gastroparesis, focusing on pathogenesis, diagnosis, and management.
RESULTS: The review intricately explores the pathogenesis contributing to diabetic gastroparesis, emphasizing autonomic neuropathy, oxidative stress, inflammation, hormonal dysregulation, microbiota alterations, and gastrointestinal neuropathy. Primary management strategies are underscored, including lifestyle modifications, symptom relief, and glycemic control. The discussion encompasses pharmacological and surgical options, highlighting the importance of a multidisciplinary approach involving various healthcare professionals for comprehensive patient care.
CONCLUSION: This review offers a thorough understanding of pathogenesis, diagnosis, and management of diabetic gastroparesis, underlining evolving approaches for clinicians. A multidisciplinary approach is crucial to address both the physical and mental health aspects of diabetes and its complications.
The invention discloses a kind of extracting method of corter pseudolaricis active material, comprise the steps of：(1) corter pseudolaricis is taken, is cleaned up, is ground into powder.(2) pretreated corter pseudolaricis powder is placed in three-necked flask, is added ethanol and N N-dimethylformamides and alkali, immersion, is adjusted pH value.(3) condensation reagent triphenyl phosphorus, stirring and dissolving, oil bath heating, during which condensing reflux are added.(4) repeat 23 times, extract solution micro porous filtration, collect extraction filtrate.(5) extract solution is concentrated under reduced pressure, obtains concentrate.(6) concentrate is dried, obtains corter pseudolaricis active material.The present invention can make a part of extract be translates directly into corresponding derivative in extraction process, increase the antibacterial effectiveness of extraction of substance, solution is first extracted in the prior art, then carries out the disadvantage of derivative conversion.
Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
PURPOSE:To obtain a hair nourishing and growing agent exhibiting excellent anti-seborrheic effect and simultaneously bringing out good hair nourishing, growing and alopecia-preventing action and having high safety over a long period by combinedly using extracts of Hypericum and an anti-seborrheic agent. CONSTITUTION:The hair nourishing and growing agent is obtained by combining an extract of Hypericum with an anti-seborrheic agent (e.g. diethylstilbestrol or acetic acid chlormadinone). The extract of Hypericum is obtained by pulverizing whole grass of hypericaeae or either one of leaf, stem, root, fruit, seed and flower thereof and extracting the pulverized plant. This extract is blended in a hair nourishing and growing agent in an amount of 0.001-10wt.% based on dried weight. The anti-seborrheic agent is preferably blended in an amount of 0.001-5wt.%. Then, this hair nourishing and growing agent contains especially preferably further carbon dioxide.
Embodiments of the present disclosure include methods and compositions related to CD 70-targeting polypeptides. In certain aspects, anti-CD 70 antibodies are disclosed. In some aspects, chimeric receptors engineered to bind CD70 are disclosed. Also disclosed are immune cell adaptors comprising a CD70 binding region and one or more immune cell binding regions. Cells (e.g., NK cells, T cells) expressing CD 70-targeting peptides are described. Methods of treatment using the polypeptides of the present disclosure are also described.
Haemobiological compsns. contg. 8-(3-(tert.-butylamino)-2- hydroxy-propoxy)- thiachroman (I), or its addn. salts, pref. the hydrochloride, in doses of 2.5-15 mg, mixed with or added to a non-toxic, inert, pharmaceutically-acceptable excipient is new. The compsns. have a positive effect on the normalisation of blood platelet properties, blood viscosity and erythrocyte deformability. The known beta-blocking activity of (I) are shown in animals at dose levels of 10-100 microgram/kg and in humans at about 1 mg; the antihypertensive properties are shown in humans and other animals at doses a little above these levels. The haemobiological activity appears at dose levels of 1-10 mg/kg, i.e. at much higher dose levels than the beta-blocking activity. Tests show (I) have no cellular membrane stabilising properties (which is usual in beta-blockers), but have a specific thromboxane-synthetase inhibitory action, without reducing prostacycline formation. It appears (I) acts at the prostaglandin metabolism level, blocking the formation of thromboxanes, without disturbing the endoperoxide formation. (I) also has fibrinolytic activity and helps redissolve thrombi. The compsns. are used to treat vascular troubles such as blood vessel wall problems in hypertension, arteriosclerosis, cerebral and cardiac vascular problems and circulatory problems due to high blood viscosity. They may be administered orally, parenterally or rectally using classical formulations. Typical doses are 5-50 mg administered 1-4 times daily. Activity tests are described.
Rituximab 375 milligrams per square meter (mg/m\^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
Despite its power in identifying highly potent ligands for select protein targets, conventional medicinal chemistry is limited by its low throughput and lack of proteomic selectivity information. We seek to develop a chemoproteomic approach for discovering covalent ligands for protein targets in an unbiased, high-throughput manner. Tripartite probe compounds composed of a heterocyclic core, an electrophilic 'warhead' and an alkyne tag have been designed and synthesized for covalently labeling and identifying targets in cells. We have developed a novel condensation reaction to prepare 2-chloromethylquinoline (2-CMQ), a novel electrophilic heterocycle. These chloromethylquinolines potently and covalently bind to a number of cellular protein targets including Prostaglandin E Synthase 2 (PTGES2), a critical regulator of cell proliferation, apoptosis, angiogenesis, inflammation, and immune surveillance. The 2-CMQs that we have developed here are novel PTGES2 inhibitors that have the potential to serve as novel therapies for the treatment of human diseases such as inflammation. Beyond this case study, our methodology can be extended to additional electrophiles and scaffolds for discovering covalent ligands for diverse targets in the human proteome.
OBJECTIVE: Observational studies show that hypertensive disorders of pregnancy (HDPs) are related to unfavourable maternal cardiovascular disease (CVD) risk profiles later in life. We investigated whether genetic liability to pre-eclampsia/eclampsia and gestational hypertension is associated with CVD risk factors and occurrence of CVD events.
METHODS: We obtained genetic associations with HDPs from a genome-wide association study and used individual participant data from the UK Biobank to obtain genetic associations with CVD risk factors and CVD events (defined as myocardial infarction or stroke). In our primary analysis, we applied Mendelian randomisation using inverse-variance weighted regression analysis in ever pregnant women. In sensitivity analyses, we studied men and nulligravidae to investigate genetic liability to HDPs and CVD risk without the ability to experience the underlying phenotype.
RESULTS: Our primary analysis included 221 155 ever pregnant women (mean age 56.8 (SD 7.9) years) with available genetic data. ORs for CVD were 1.20 (1.02 to 1.41) and 1.24 (1.12 to 1.38) per unit increase in the log odds of genetic liability to pre-eclampsia/eclampsia and gestational hypertension, respectively. Furthermore, genetic liability to HDPs was associated with higher levels of systolic and diastolic blood pressure and younger age at hypertension diagnosis. Sensitivity analyses revealed no statistically significant differences when comparing the findings with those of nulligravidae and men.
CONCLUSIONS: Genetic liability to HDPs is associated with higher CVD risk, lower blood pressure levels and earlier hypertension diagnosis. Our study suggests similar findings in ever pregnant women, nulligravidae and men, implying biological mechanisms relating to HDPs are causally related to CVD risk.
The invention discloses a robust drug recommendation method and a system based on sparse attention mechanism and graph representation learning, and belongs to the technical field of natural language processing. The invention uses sparse attention network to learn different types of medical information in the patient history visit to remove noise data in the patient history visit and obtain better patient representation. The pictorial learning module is used to enhance the guidance of different types of medical knowledge on the recommendation results. And finally, further improving the robustness of the method through multi-task joint learning. The invention solves the problems of noise in the patient history data in the current medicine recommendation task, insufficient consideration of different types of medical knowledge, poor robustness of recommendation in complex medical environments facing data deficiency and the like. The method not only improves the precision of the performance on the task and enhances the robustness of the model, but also has reference significance for other tasks with similar problems.
For patients who randomize to CTM: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the CTM Flow material. A 23, or 20 gauge needle will be used to inject the CTM after arthroplasty and prior to closure of the capsule. To draw up the injection: allow the particulate to settle to the bottom and withdrawal fluid into the 3 or 5 cc syringe. It is ok if some particulate is drawn up into the syringe. 2cc of CTM will be injected into each patient.
Psychological characterization of patients affected by Inflammatory Bowel Disease (IBD) focuses on comorbidity with psychiatric disorders, somatization or alexithymia. Whereas IBD patients had higher risk of stable anxiety and depression for many years after the diagnosis of the disease, there is a lack of studies reporting a comprehensive psychosomatic assessment addressing factors of disease vulnerability, also in the long-term. The objective of this investigation is to fill this gap in the current literature. The aims were thus to assess: a) changes between baseline and a 4-year follow-up in psychiatric diagnoses (SCID), psychosomatic syndromes (DCPR), psychological well-being (PWB-I), lifestyle, gastrointestinal symptoms related to IBD and Irritable Bowel Syndrome (IBS)-like symptoms b) stability of psychiatric and psychosomatic syndromes at 4-year follow-up. A total of 111 IBD outpatients were enrolled; 59.5% of them participated at the follow-up. A comprehensive assessment, including both interviews and self-report questionnaires, was provided at baseline and follow-up. Results showed increased psychiatric diagnoses, physical activity, consumption of vegetables and IBS-like symptoms at follow-up. Additionally, whereas psychiatric diagnoses were no longer present and new psychopathological pictures ensued at follow-up, more than half of the sample maintained psychosomatic syndromes (particularly allostatic overload, type A behavior, demoralization) from baseline to follow-up. Long-term presence/persistence of such psychosocial burden indicates the need for integrating a comprehensive psychosomatic evaluation beyond traditional psychiatric nosography in IBD patients. Moreover, since psychosomatic syndromes represent vulnerability factors of diseases, further studies should target subgroups of patients presenting with persistent psychosomatic syndromes and worse course of the disease.
INTRODUCTION: This study aimed to assess the short-term complication rate after US-guided core needle biopsies with an 18-gauge needle of retroperitoneal or intraabdominal masses (non-kidney group) compared with complications after biopsy from a renal mass (kidney group).
METHODS: This was a retrospective analysis of 330 consecutive patients in the non-kidney group and 330 control patients in the kidney group. We recorded baseline characteristics, diagnostic yield, complications graded as Clavien-Dindo (CD) and readmissions within one and seven days.
RESULTS: In all, 245 patients in the non-kidney and 281 patients in the kidney group had a biopsy performed. A total of 54 (22%) patients in the non-kidney group had a complication registered. However, 47 were minor complications (minor bleeding or localised pain, CD 1). In the kidney group, 47 (17%) patients had a complication, with 44 being graded as CD 1. No major complications (CD 3 or higher) were associated with the biopsies. Only 0.8% of patients in the non-kidney group and 0.7% in the kidney group had a treatment-requiring CD 2 complication (i.e. blood transfusion) directly caused by the US-guided biopsy. These complications were recognised less than 30 minutes or more than four hours after the procedure. We found no significant difference in the complication rate, diagnostic yield or risk of re-admission between the two groups.
CONCLUSION: The observation period for patients who undergo an uncomplicated US-guided biopsy from an intraabdominal or retroperitoneal mass can safely be reduced to 30 minutes.
FUNDING: None TRIAL REGISTRATION. Not relevant.